An underground market for unapproved slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.
Experimental Treatment Gaining Popularity Online
Retatrutide, which is still in clinical trials, is being advertised by online personalities for its alleged fat-burning properties. Followers are encouraged to message these profiles privately for supplier links, while also obtaining promotional offers.
Thriving Commerce on Messaging Platforms
Separately, a robust market exists on messaging services, where groups with thousands of participants share “before and after” images, administration instructions and assertions of rapid UK delivery. Sellers promote the drug there before redirecting buyers to other platforms for transactions.
Learning About The Experimental Drug
This medication is an experimental injectable developed by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies indicate it could help individuals reduce up to 25% of their body weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.
Medical Experts Voice Concerns
However, doctors and pharmacists have cautions that the distribution of what remains an unlicensed drug in the UK is worrisome and could lead to users administering products of unknown origin.
Several experts said the demand for retatrutide could be connected to the rising price of licensed slimming treatments such as Mounjaro.
Legal Status and Enforcement
Selling retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.
Several influencers attempt to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but promotion and supply can still violate pharmaceutical, marketing, and customer regulations, risking penalties, legal action or prison.
Platform Reaction and Material Removal
Based on the social media company, the platform has removed problematic material and prohibited related keywords and query recommendations. The company stated it was dedicated to keeping the service secure and allocating resources in enhancing compliance measures.
Digital Trading Operations
Research also discovered groups with up to nine thousand members marketing retatrutide using the platform's built-in search feature, which functions like a public directory. Typing “retatrutide” instantly displays groups with thousands of users, populated with images of weight loss, positive testimonials and step-by-step guides for mixing or injecting at home.
Within minutes of entering one group, a vendor posted contact information, where most transactions take place. The seller sent an instruction manual and promised shipping within two days. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one asked about weight, health issues or previous experience.
Item Details and Pricing
Inside these communities, messages show black plastic parcels with Royal Mail labels, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens usually priced at 160 pounds for 20mg. When asked how much time a pen should be used, sellers give conflicting responses ranging from a few weeks to “depends on your body”.
Platform Moderation and Security Actions
A spokesperson for the messaging service stated it actively moderated harmful material on its platform including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“People are injecting materials they cannot confirm. Although the science behind this drug is valid, these online products may not include what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to recent cost increases for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are using online platforms. But counterfeit injections are highly risky. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she explained.
Her team has previously seen patients harmed by self-injection from unconfirmed sources. “We recognize the frustration, but buying from messaging apps or WhatsApp is taking chances with your well-being,” stated the doctor. “These materials could be impure or incorrectly dosed.”
Producer Statement
A representative from Eli Lilly said retatrutide was in phase 3 research studies and had not been evaluated or approved by any government authority globally. “Therefore at this time no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company experimental product not yet approved … may subject users to possibly significant medical dangers”.
